We developed a 2 step approach to HI HSCT in which a fixed dose of allogeneic T cells are infused after reduced intensity (RIC) or myeloablative conditioning (HSCT step 1). After 2-3 days, cyclophosphamide (CY) 60 mg/kg/d x 2 is given to establish bidirectional tolerance. One day after the CY, a CD 34 selected stem cell product is infused (HSCT step 2).
This approach has been associated with a low incidence of non-relapse mortality (NRM) resulting in a significant improvement in overall survival (OS) in patients (pts) undergoing HI HSCT at our institution. This abstract examined the predictability of this tool in pts undergoing the 2 step HI HSCT.
Recommended CitationPalmisiano, MD, Neil D.; Gaballa, MD, Sameh; Alpdogan, Onder; Carabasi, MD, Matthew; Filicko-O'Hara, MD, Joanne; Kasner, MD, Margaret; Martinez-Outshoorn, MD, Ubaldo E.; Wagner, MD, John L.; Weiss, MD, Mark; Flomenberg, MD, Neal; and Grosso, DNP, Dolores, "Hematopoietic Cell Transplant Co-Morbidity Index (HCT-CI): Ability to Predict Outcomes in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)" (2014). Department of Medical Oncology Faculty Papers. Paper 28.